Refine by MP, party, committee, province, or result type.

Results 76-90 of 106
Sorted by relevance | Sort by date: newest first / oldest first

Justice committee  I am not a parent. I would take exception, however, to the implicit suggestion that those of us who are not parents somehow don't care about the welfare of young people. I think that's clearly not true. I have young people in my life; I care about them very much. I think Mr. Jon

April 27th, 2009Committee meeting

Richard Elliott

Justice committee  I might briefly add some information from both the U.S. context and from Vancouver. When you look at the experience in the U.S., studies have shown that just over 5% of federal prisoners who are in prison for offences involving crack cocaine and 11% of federal drug defendants ar

April 27th, 2009Committee meeting

Richard Elliott

Justice committee  Merci bien. Indeed, the example you gave would result in a mandatory minimum prison term of two years for that particular person--that's one of the examples in our brief--if there are reasons to believe that people under the age of 18 regularly frequent the campus of the Univers

April 27th, 2009Committee meeting

Richard Elliott

Justice committee  Thank you. Very briefly, the evidence on drug treatment courts, as the two previous speakers have suggested, is equivocal. There are any number of justice system actors in the U.S., where they have a much more extensive system of drug treatment courts, that are raising very seri

April 27th, 2009Committee meeting

Richard Elliott

Justice committee  I will simply end by asking that the government withdraw Bill C-15 and that members of other parties vote against this legislation. Thank you.

April 27th, 2009Committee meeting

Richard Elliott

Justice committee  Thank you, Mr. Chair and committee members, for the opportunity to speak with you today. The Canadian HIV/AIDS Legal Network is a national non-governmental organization, an NGO, with special consultative status with the United Nations. Its mission is to promote law and policy tha

April 27th, 2009Committee meeting

Richard Elliott

Industry committee  That should be part of the solution but it is not the only recommendation we have made in our brief. There are other important recommendations, especially on the compulsory license process which should be simplified. Eliminating the list is part of the solution but is not the who

April 18th, 2007Committee meeting

Richard Elliott

Industry committee  Thank you.

April 18th, 2007Committee meeting

Richard Elliott

Industry committee  With great respect to our colleagues at Industry Canada, I find it hard to imagine that a brand name pharmaceutical company is going to be able to go credibly before a court in Canada and say that particular tablet is not a pharmaceutical product. If your legislation says you ca

April 18th, 2007Committee meeting

Richard Elliott

Industry committee  Well, that's the entire purpose of this legislation, to allow for the patent to be overridden and to authorize a generic manufacturer to make it. But the notion that we need a list of specifically named drugs in order to resolve any confusion about whether a particular drug is a

April 18th, 2007Committee meeting

Richard Elliott

Industry committee  First, I want to clarify something. When the legislation was being discussed, there was no consensus on the fact that there should be a list. On the contrary, all the NGOs were opposed to the creation of that limited list. As Mrs. Perkins explained, we said that there was no need

April 18th, 2007Committee meeting

Richard Elliott

Industry committee  Thank you, Mr. Chair. Let me comment briefly on your first question. Certainly, I don't think any of the NGOs that are working in the struggle against HIV or for health generally would be unhappy to see CIDA put up more money to help support health in developing countries. Indee

April 18th, 2007Committee meeting

Richard Elliott

Industry committee  To the best of my knowledge, none of the other half-dozen or so jurisdictions that have adopted something similar to the Canadian regime have moved to the step of doing the kind of review Canada is now doing. That's probably partly because Canada was one of the first to move on t

April 18th, 2007Committee meeting

Richard Elliott

Industry committee  It has in fact proven to be a problem, and that's why we're suggesting the simpler, slightly different process that we've outlined. As you heard from MSF, despite all of their efforts, because the Canadian legislation requires that there be a tentative contract with a particular

April 18th, 2007Committee meeting

Richard Elliott

Industry committee  I can speak to that. Our central recommendation, which I think would help answer your question, and it's something that Ms. Perkins has already mentioned, is to simplify this process by letting the generic manufacturer here in Canada get one compulsory licence at the beginning o

April 18th, 2007Committee meeting

Richard Elliott